We publish the position of the Polish Society of Rheumatology on the availability of innovative therapies for patients with rheumatic diseases
The Polish Society of Rheumatology informs that from May 1, 2022, the drug Benepali containing the biosimilar etanercept is no longer reimbursed in drug programs in rheumatology. This is a continuation of the previously observed trend of withdrawing biological drugs from Poland, including bioequivalent ones, by some marketing authorization holders.
Currently, reimbursement under the above-mentioned The programs cover the following medicinal products (in alphabetical order of active substance name and medicinal product names):
- adalimumab (Amgevita, Humira, Hyrimoz, Idacio),
- baricitinib (Olumiant),
- certolizumabpegol (Cimzia),
- etanercept (Enbrel, Erelzi),
- golimumab (Simponi),
- infliximab (Flixabi, Remicade, Remsima, Zessly),
- ixekizumab (Taltz),
- rituximab (Mabthera, Riximyo),
- secukinumab (Cosentyx),
- tocilizum...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
